According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...

Researchers at MIT and the Scripps Research Institute have shown that they can generate a strong immune response to HIV with ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine ...

The Trump administration has ended a program seeking a vaccine for HIV, the first in a series of decisions that is leaving ...

In the quest to develop an effective HIV vaccine, scientists from Scripps Research have made a significant leap forward. They ...